Suppr超能文献

正性肌力药和血管扩张剂疗法对充血性心肌病患者舒张功能的不同影响。

The differential effects of positive inotropic and vasodilator therapy on diastolic properties in patients with congestive cardiomyopathy.

作者信息

Carroll J D, Lang R M, Neumann A L, Borow K M, Rajfer S I

出版信息

Circulation. 1986 Oct;74(4):815-25. doi: 10.1161/01.cir.74.4.815.

Abstract

Symptoms of congestive heart failure frequently reflect abnormalities in both systolic and diastolic performance. While much work has been reported regarding the mechanisms by which positive inotropic and vasodilator therapy affect systolic performance, little is known about their effect on diastolic function. In 12 patients with diffuse congestive cardiomyopathy micromanometer left ventricular and aortic pressure measurements were recorded simultaneously with two-dimensionally targeted M mode echocardiograms and thermodilution-determined cardiac output. Each patient received dopamine (2, 4, and 6 micrograms/kg/min), and dobutamine (2, 6, and 10 micrograms/kg/min), and 10 received nitroprusside (0.125 to 2.0 micrograms/kg/min). Baseline hemodynamics were characterized by low cardiac index (2.1 +/- 0.7 liter/min/m2, mean +/- SD), high left ventricular end-diastolic pressure (24 +/- 10 mm Hg), and increased end-diastolic (6.8 +/- 1.0 cm) and end-systolic dimensions (6.0 +/- 1.0 cm). All patients had abnormal left ventricular pressure decay with a prolonged time constant (67 +/- 20 msec) and reduced peak diastolic lengthening rates. Dopamine and dobutamine decreased the time constant of relaxation and increased the peak lengthening rate. Dobutamine also reduced the minimum diastolic pressure from 14 +/- 7 to 10 +/- 9 mm Hg (p less than .01); neither drug reduced end-diastolic pressure. In fact, dopamine elevated end-diastolic pressures in seven patients, despite more rapid pressure decay. Diastolic pressure-dimension relations after dopamine and dobutamine showed a leftward shift with a reduced end-systolic chamber size, but no significant changes in passive chamber stiffness. Nitroprusside decreased left ventricular minimum diastolic pressure by 4 +/- 2 mm Hg and end-diastolic pressure by 7 +/- 4 mm Hg (p less than .01). It did not consistently accelerate left ventricular pressure decay at the doses tested. The decreased end-diastolic pressure with nitroprusside was due to a reduced end-diastolic dimension in five patients. In the other patients, all of whom had elevated right atrial pressures, diastolic pressure-dimension relations showed a parallel downward shift after nitroprusside. Thus, positive inotropic therapy with beta 1-adrenoceptor agonists enhances early diastolic distensibility by accelerating relaxation, augmenting filling, and reducing end-systolic chamber size. Vasodilator therapy is much more effective in lowering diastolic pressures.(ABSTRACT TRUNCATED AT 400 WORDS)

摘要

充血性心力衰竭的症状常常反映出收缩功能和舒张功能均异常。虽然已有大量关于正性肌力药和血管扩张剂治疗影响收缩功能机制的报道,但对于它们对舒张功能的影响却知之甚少。对12例弥漫性充血性心肌病患者,同时用二维靶向M型超声心动图和热稀释法测定心输出量记录微测计左心室和主动脉压力。每位患者接受多巴胺(2、4和6微克/千克/分钟)、多巴酚丁胺(2、6和10微克/千克/分钟)治疗,10例患者接受硝普钠(0.125至2.0微克/千克/分钟)治疗。基线血流动力学特征为低心指数(2.1±0.7升/分钟/平方米,平均值±标准差)、高左心室舒张末期压力(24±10毫米汞柱)以及增加的舒张末期(6.8±1.0厘米)和收缩末期内径(6.0±1.0厘米)。所有患者左心室压力衰减均异常,时间常数延长(67±20毫秒)且舒张期峰值延长率降低。多巴胺和多巴酚丁胺缩短了舒张时间常数并增加了峰值延长率。多巴酚丁胺还将最低舒张压从14±7毫米汞柱降至10±9毫米汞柱(p<0.01);两种药物均未降低舒张末期压力。实际上,尽管压力衰减更快,但多巴胺使7例患者的舒张末期压力升高。多巴胺和多巴酚丁胺治疗后的舒张压-内径关系显示向左移位,收缩末期腔室大小减小,但被动腔室僵硬度无显著变化。硝普钠使左心室最低舒张压降低4±2毫米汞柱,舒张末期压力降低7±4毫米汞柱(p<0.01)。在所测试的剂量下,它并未持续加速左心室压力衰减。硝普钠导致舒张末期压力降低是由于5例患者的舒张末期内径减小。在其他所有右心房压力升高的患者中,硝普钠治疗后舒张压-内径关系显示平行向下移位。因此,用β1肾上腺素能受体激动剂进行正性肌力治疗可通过加速舒张、增加充盈和减小收缩末期腔室大小来增强舒张早期的扩张性。血管扩张剂治疗在降低舒张压方面更为有效。(摘要截选至400字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验